PUBLICATIONS

(Noted in Scientific Information’s “Highly Cited Authors In Science” list, having been cited more than 36,000 times with an h-index score of 84)

Refereed Articles


73. Sadovnick AD, Ebers GC, Paty DW, Eisen K. Cause of death in patients attending multiple


122. Willer CJ, Ebers GC. Susceptibility to multiple sclerosis: interplay between genes and environment.


128. Ebers GC, Yee IML, Sadnovnik AD, Duquette P and the Canadian Collaborative Study Group.


140. Ebers GC. The Natural History of Multiple Sclerosis. JNNP 2001 Dec, 71 Suppl 2, ii16-ii19.


173. Willer CJ, Herrera B, Morrison KM, Sadovnick AD, Ebers GC, for the Canadian Collaborative Study on Genetic Susceptibility to Multiple Sclerosis. Association between microchimerism and multiple


189. Willer CJ, Dyment DA, Cherny S, Ramagopalan SV, Herrera BM, Morrison KME, Sadovnick AD,


204. Ramagopalan SV, Dyment DA, Herrera BM, DeLuca GC, Lincoln MR, Orton SM, Handunnetthi L, Chao MJ, Sadovnick AD and Ebers. GC. Methylation of class II transactivator gene promoter IV is


251. Ebers GC. Outcome measures were flawed. BMJ 2010;340:c2707.


<table>
<thead>
<tr>
<th>Number</th>
<th>Reference</th>
</tr>
</thead>
</table>
BOOKS


BOOK CHAPTERS


LETTERS


7. Petkau AJ, Ebers GC, Reder AT. (letter to the editor). Response to Deisenhammer and
Giovannoni to paper Longitudinal analyses of the effect of neutralizing antibodies etc. Multiple Sclerosis 2004; 10: 715


22


EDITORIALS


PUBLICATIONS EDITED


ABSTRACTS


26. Ebers GC, Paty DW, Moulin DW. The predictive value of CSF electrophoresis in "possible MS".


60. Ebers GC. Twin studies in multiple sclerosis. XIVth World Congress of Neurology. New Delhi,


105. Dyment D.A., Datta, A., Armstrong H., Canadian Collaborative Study Group, Sadovnick, A.D.,


114. Sadovnick AD, Yee I, Ebers GC. Birth Order in Multiple Sclerosis: Canadian Data (ABSTRACT) ECTRIMS, September 2005, Thessaloniki, Greece.


118. Ebers GC et al. Expression of the Multiple Sclerosis associated MHC Class II allele HLA-DRB1*1501 is Regulated by Vitamin D. Presented at ANA meeting Salt Lake City, September 2008
119. DiSanto et al. HLA-DRB1 confers increased risk of pediatric-onset ms in children with acquired demyelination. 10th International Congress of Neuroimmunology, in Sitges (Barcelona, Spain) from October 26th to 30th, 2010. Oral presentation

120. H Hanwell et al. HLA-DRB1*15 and vitamin D status at first demyelinating episode are independent risk factors for MS in children. ECTRIMS. Gothenburg 13-16 October 2010.

PROFESSOR G.C. EBERS -- INVITED LECTURES

1. Idiotypes in SSPE and MS Rockefeller University, New York, NY September 1977
2. Idiotypes in SSPE and MS Cornell University Medical Center, NY Hospital, Department of Neurology September 1977
3. HLA and MS Cornell University Medical Center, NY Hospital, Department of Neurology September 1977
4. Idiotypes in SSPE and MS Scripps Clinic, La Jolla, California February 1978
5. Idiotypic Determinants in SSPE St Michael's Hospital, University of Toronto, Department of Medicine February 1978
6. Idiotypes in SSPE and MS Department of Neurology, Vancouver General Hospital, UBC June 1981
7. Osler and Neurology Emory University, Department of Neurology, Atlanta, Georgia December 1981
8. CSF in the Diagnosis & Prognosis of MS Emory University, Department of Neurology, Atlanta, Georgia December 1981
9. HLA and MS Emory University, Department of Neurology, Atlanta, Georgia December 1981
10. Prognosis in MS Emory University, Department of Neurology, Atlanta, Georgia December 1981
11. Idiotypic Determinants in MS & SSPE Emory University, Department of Neurology, Atlanta, Georgia December 1981
12. CSF in the Diagnosis of MS University Hospital, UBC, Department of Neurology, Vancouver B.C. June 1982
13. Osler and Neurology Vancouver General Hospital, UBC, Vancouver, BC
<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Venue</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>MS - Environment vs Genetics</td>
<td>Notre Dame Hospital, University of Montreal, Montreal, Quebec</td>
<td>January 1982</td>
</tr>
<tr>
<td>15</td>
<td>MS: nature or nurture</td>
<td>Neuroscience Seminar, Queen's University, Kingston, Ontario</td>
<td>February 1982</td>
</tr>
<tr>
<td>16</td>
<td>HLA and MS</td>
<td>Dept of Immunology, Memorial University, St.John's, Nfld.</td>
<td>February 1982</td>
</tr>
<tr>
<td>17</td>
<td>Idiotypes in MS</td>
<td>Memorial University, Dept. of Immunology, St. John's, Nfld.</td>
<td>February 1982</td>
</tr>
<tr>
<td>18</td>
<td>The Genetics of MS</td>
<td>Rockefeller University, Dept. of Immunology, New York, NY</td>
<td>April 1982</td>
</tr>
<tr>
<td>19</td>
<td>The Immunology of MS CSF</td>
<td>Cornell Medical Center, New York Hospital, New York, NY</td>
<td>April 1982</td>
</tr>
<tr>
<td>20</td>
<td>Genetics vs Environment in MS</td>
<td>Cornell Medical Center, New York Hospital, New York, NY</td>
<td>April 1982</td>
</tr>
<tr>
<td>21</td>
<td>Diagnostic Criteria in MS -</td>
<td>The Diagnosis of MS, Washington DC</td>
<td>April 1982</td>
</tr>
<tr>
<td>22</td>
<td>The Immunogenetics of MS</td>
<td>University of Louvain, Brussels, Belgium</td>
<td>February 1983</td>
</tr>
<tr>
<td>23</td>
<td>Idiotypes in MS</td>
<td>University of Louvain, Brussels, Belgium</td>
<td>February 1983</td>
</tr>
<tr>
<td>24</td>
<td>HLA and MS</td>
<td>Laboratory of Jean Dausset, Hospital St. Louis, Paris, France</td>
<td>February 1983</td>
</tr>
<tr>
<td>25</td>
<td>Sib Pair Analysis in MS</td>
<td>Laboratory of Jean Dausset, Hospital St. Louis, Paris, France</td>
<td>February 1983</td>
</tr>
<tr>
<td>26</td>
<td>Immunology of MS</td>
<td>International Federation of Multiple Sclerosis Societies, Vancouver, B.C.</td>
<td>September 1983</td>
</tr>
<tr>
<td>27</td>
<td>Oligoclonal Bands in MS</td>
<td>New York Academy of Science, Symposium on MS,New York, NY</td>
<td>December 1983</td>
</tr>
<tr>
<td>28</td>
<td>Immunogenetics of MS</td>
<td>Cornell University Medical Center Symposium, New York, NY</td>
<td>December 1983</td>
</tr>
<tr>
<td>29</td>
<td>Genetic Factors in MS</td>
<td>Rockefeller University, New York, NY</td>
<td>December 1983</td>
</tr>
<tr>
<td>31</td>
<td>The Genetics of MS</td>
<td>Welsh National School of Medicine, Cardiff, Wales</td>
<td>January 1984</td>
</tr>
<tr>
<td>32</td>
<td>The Nature of MS Susceptibility</td>
<td>Emory University, Atlanta, Georgia</td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>Title</td>
<td>Location</td>
<td>Event Date</td>
</tr>
<tr>
<td>-----</td>
<td>--------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>33.</td>
<td>Osler and Neurology</td>
<td>American Osler Society, Atlanta, Georgia</td>
<td>April 1984</td>
</tr>
<tr>
<td>34.</td>
<td>Osler and MS</td>
<td>Oslerfest, Oxford, England</td>
<td>September 1984</td>
</tr>
<tr>
<td>35.</td>
<td>The Genetics of MS</td>
<td>World Federation of Neurology, Satellite Symposium - MS</td>
<td>September 1985</td>
</tr>
<tr>
<td>36.</td>
<td>Genetic Factors in MS</td>
<td>The MS Societies of Great Britain &amp; Northern Ireland National Hospital, Queen Square, London, England</td>
<td>September 1985</td>
</tr>
<tr>
<td>37.</td>
<td>Genetics of MS</td>
<td>Asilomar Conference, National U.S. MS Society, California</td>
<td>November 1985</td>
</tr>
<tr>
<td>38.</td>
<td>Gm Allotyes and MS</td>
<td>International Federation of MS Societies, NATO Symposium on Advanced Research, Belgium</td>
<td>April 1986</td>
</tr>
<tr>
<td>39.</td>
<td>MS - Nature or Nurture</td>
<td>University of Pennsylvania, Philadelphia, PA</td>
<td>May 1986</td>
</tr>
<tr>
<td>40.</td>
<td>Prognosis in M.S.</td>
<td>University of Pennsylvania, Philadelphia, PA</td>
<td>May 1986</td>
</tr>
<tr>
<td>41.</td>
<td>Prognostic Factors in MS</td>
<td>Association of Life Insurance Medical Directors of America, Ottawa, Ontario</td>
<td>October 1986</td>
</tr>
<tr>
<td>42.</td>
<td>Genetic Studies in MS</td>
<td>University of Texas, Department of Neurology, Dallas, Texas</td>
<td>October 1986</td>
</tr>
<tr>
<td>43.</td>
<td>Osler and Neurology</td>
<td>University of Texas, Department of Neurology, Dallas, Texas</td>
<td>October 1986</td>
</tr>
<tr>
<td>44.</td>
<td>Recent Advances in MS</td>
<td>North Texas Chapter, Multiple Sclerosis Society, Dallas, Texas</td>
<td>October 1986</td>
</tr>
<tr>
<td>45.</td>
<td>Prognosis in MS</td>
<td>Rationale for Treatment International Congress, Virology &amp; Immunology in MS, University of Milan, Milan, Italy</td>
<td>December 1986</td>
</tr>
<tr>
<td>46.</td>
<td>Genetics &amp; Epidemiology of MS</td>
<td>University of Liverpool, Department of Neurology &amp; Medical School, Liverpool, UK</td>
<td>April 1987</td>
</tr>
<tr>
<td>47.</td>
<td>Genetics of MS</td>
<td>John Radcliffe Infirmary, Department of Neurology, Oxford University, Oxford, UK</td>
<td>April 1987</td>
</tr>
<tr>
<td>48.</td>
<td>Genetics of MS</td>
<td>John Radcliffe Hospital, Department of Molecular Hematology, Headington, Oxford, UK</td>
<td>April 1987</td>
</tr>
<tr>
<td>49.</td>
<td>Genetics of MS</td>
<td>National Hospital for Nervous Diseases, Queen Square, London, UK</td>
<td>June 1987</td>
</tr>
<tr>
<td>50.</td>
<td>Discussant</td>
<td>Board of MS Society of Great Britain &amp; Northern Ireland, Royal</td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>Title</td>
<td>Institution and Location</td>
<td>Date</td>
</tr>
<tr>
<td>-----</td>
<td>--------------------------------------------</td>
<td>---------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>51.</td>
<td>Genetics of MS</td>
<td>Max Planck Institute for Studies in Demyelinating Disease,</td>
<td>June 1987</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wurzburg, Germany</td>
<td></td>
</tr>
<tr>
<td>52.</td>
<td>Prognosis in MS</td>
<td>Welsh National School of Medicine, Cardiff, Wales</td>
<td>August 1987</td>
</tr>
<tr>
<td>53.</td>
<td>Natural History of MS</td>
<td>5th ECTRIMS Congress, European Committee for Treatment &amp;</td>
<td>March 1989</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Research in MS, Brussels, Belgium</td>
<td></td>
</tr>
<tr>
<td>54.</td>
<td>Genetics &amp; MS</td>
<td>University of Alabama, Birmingham, Alabama</td>
<td>April 1989</td>
</tr>
<tr>
<td>55.</td>
<td>Genes and Susceptibility to MS</td>
<td>Workshop Chairman, National MS Society(USA), Cambridge, UK</td>
<td>July 1989</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>56.</td>
<td>Clinics of MS</td>
<td>Karolinska Institutet, Stockholm, Sweden</td>
<td>October 1989</td>
</tr>
<tr>
<td>57.</td>
<td>14th World Congress of Neurology International Federation of MS Societies</td>
<td>New Delhi, India</td>
<td>October 1989</td>
</tr>
<tr>
<td>58.</td>
<td>IFFMSS, Inaugural Pringle Lectureship &amp; Recipient of Pringle Medal</td>
<td>Dublin, Ireland</td>
<td>October 1990</td>
</tr>
<tr>
<td>59.</td>
<td>Visiting Professor</td>
<td>University of British Columbia, Vancouver, BC</td>
<td>December 1990</td>
</tr>
<tr>
<td>60.</td>
<td>Genetic Epidemiology</td>
<td>Jefferson University, Philadelphia, PA</td>
<td>January 1991</td>
</tr>
<tr>
<td>61.</td>
<td>Genetic Epidemiology of MS</td>
<td>University of Minnesota, (Visiting Professor), Minneapolis,</td>
<td>April 1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Minnesota</td>
<td></td>
</tr>
<tr>
<td>62.</td>
<td>Natural History &amp; Therapeutic Trials for MS</td>
<td>University of Minnesota, Clinical Neuroscience Conference,</td>
<td>April 1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Minneapolis, Minnesota</td>
<td></td>
</tr>
<tr>
<td>63.</td>
<td>Foreign lectureship</td>
<td>Neurologic Society of Norway</td>
<td>May 1991</td>
</tr>
<tr>
<td>64.</td>
<td>Genetics of Multiple of MS</td>
<td>Mini-symposium</td>
<td>May 1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Finnish MS Society, Turku, Finland</td>
<td></td>
</tr>
<tr>
<td>65.</td>
<td>Localisation of the Gene for Paramyotonia</td>
<td>Karolinska Institutet, Huddinge, Sweden</td>
<td>May 1991</td>
</tr>
<tr>
<td></td>
<td>Congenital</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Symposium on Regulation of Autoimmunity</td>
<td></td>
</tr>
<tr>
<td>67.</td>
<td>Genetics of MS</td>
<td>Cambridge University, Cambridge, U.K.</td>
<td></td>
</tr>
<tr>
<td>68.</td>
<td>MS: an overview</td>
<td>Karolinska Institutet, Huddinge, Sweden</td>
<td>January 1992</td>
</tr>
<tr>
<td>69.</td>
<td>Linkage Study of MS</td>
<td>Institute of Molecular Medicine, Oxford, UK</td>
<td></td>
</tr>
</tbody>
</table>
70. Argentina Neurological Society Foreign Speaker  
Buenos Aires  
September 1992

71. 2nd WEHI Research Meeting - Progress in MS Research  
Walter & Eliza Hall Institute of Medical Research, Melbourne, Australia  
October 1992

72. 1. Natural History of MS ; 2. History of MS; 3. Genetic Epidemiology of MS  
Department of Neurology, University of Auckland, New Zealand  
November 1992

73. Genetic Epidemiology of MS  
Dept. of Neurology, Mayo Clinic, Rochester, Minnesota  
September 1993

74. MS Conference - MS Research Update  
MS Society of Canada, Saskatchewan Division, Saskatoon, SK  
October 1993

75. 1. MS as a Polygenic Disease; 2. Molecular Genetics & Epidemiology  
Wayne State University, Grand Rounds, Neurology, Detroit, Michigan  
November 1993

76. Neuroinflammatory Diseases: 1. Natural History of MS; 2. Design & Interpretation of Clinical Trials in MS; 3. Genetic Epidemiology of MS  
Karolinska Institutet, Dept. Of Neurology, Huddinge, Sweden  
November 1993

77. 1. Early Diagnosis in MS  
2. Prognosis of MS  
The Multiple Sclerosis Group of the Spanish Neurology Society  
Barcelona, Spain  
December 1993

78. Genetic Epidemiology of MS  
University of Maryland, School of Medicine, Baltimore, MD  
April 1994

79. Prognosis in MS “Genetic Determinants of Disease Outcome”  
MS Issues Forum, Washington, D.C.  
May 1994

80. Multiple Sclerosis as a Complex Trait  
Royal College Speaker, Canadian Congress of Neurological Sciences, St. John’s, Nfld.  
June 1994

81. 1. Neuroimmunology: Immune Mechanisms, Interactions & Therapeutic Strategies  
2. MS: Natural History of the Disease  
Neurological Society of Rosario, Neurological Society of Argentina  
August 1994

82. New Treatment Perspectives in MS  
Centre for Advanced Study, University of Bergen, Oslo, Norway  
September 1994

83. Immunotherapy for MS: clinical aspects and trials  
Update Europe, Vienna, Austria  
September 1994

84. Immunotherapy for MS: clinical aspects & trials  
National MS Society of Australia, Canberra, Australia  
September 1994
<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>86.</td>
<td>MS: An Updating on Diagnosis &amp; Therapy &quot;Immunogenetics &amp; Susceptibility Markers in MS&quot;</td>
<td>XII Corso di Aggiornamento della Societa Italiana di Neurologia Bari, Italy October 1994</td>
</tr>
<tr>
<td>87.</td>
<td>MS as a Complex Trait: genes &amp; environment</td>
<td>Queen's University, Kingston, Ontario October 1994</td>
</tr>
<tr>
<td>89.</td>
<td>New Directions: management of MS</td>
<td>Berlex Grand Rounds, Health Science Communications Duke University, North Carolina February 1995</td>
</tr>
<tr>
<td>90.</td>
<td>1. CSF in the Diagnosis of Neurological Disorders; 2. Introduction to Molecular Genetics; 3. Immunotherapy of MS; 4. Molecular Genetics of Neuromuscular Disorders; 5. Molecular Genetics of the Dementias; 6. Complex Traits: Epidemiology and Genetics in MS</td>
<td>Alfred Grendel Trust Visiting Professorship, Auckland Hospital, Auckland, New Zealand February 1995</td>
</tr>
<tr>
<td>92.</td>
<td>Oslo International Think-tank on MS Epidemiology</td>
<td>Chairman-Geneics Session, Centre for Advanced Study at the Norwegian Academy of Science &amp; Letters, Norway June 1995</td>
</tr>
<tr>
<td>93.</td>
<td>Workshop on the Epidemiology &amp; Genetics of MS</td>
<td>Alghero, Sardinia June 1995</td>
</tr>
<tr>
<td>94.</td>
<td>Workshop on Genetic Models for MS &amp; Related Disorders</td>
<td>Chairman - Future Directions, National MS Society (USA), Quebec City, QC August 1995</td>
</tr>
<tr>
<td>95.</td>
<td>Genetic Susceptibility in MS</td>
<td>11th European Congress on MS, (ECTRIMS), Jerusalem, Israel September 1995</td>
</tr>
<tr>
<td>96.</td>
<td>Genetics of MS</td>
<td>Schering AG, Berlin, Germany October 1995</td>
</tr>
<tr>
<td>97.</td>
<td>Genetic Epidemiology of MS</td>
<td>IX PAN AM Congress of Neurology, Guatemala October 1995</td>
</tr>
<tr>
<td>98.</td>
<td>MS as a Complex Trait</td>
<td>Workshop on Genetic Factors in MS MS Forum, PPS Europe Ltd, Boston, MA October 1995</td>
</tr>
<tr>
<td>99.</td>
<td>1. Genetics of Movement Disorders; 2. Genetics of MS; 3. MS: Natural History; 4. Genetics of Neuromuscular Disorders</td>
<td>II Congreso Nacional de Neurologia, Barranquilla, Columbia</td>
</tr>
</tbody>
</table>
100. The Nature & Nurture of MS Susceptibility
The McEwan Professorship & Lecture, University of Toronto, Toronto, Canada
November 1995

101. The Natural & Unnatural History of MS: Neurology Research Day,
University of Toronto, Toronto, Canada
November 1995

102. Demyelinating Diseases & Infections in the Nervous System
Karolinska Institutet, Division of Neurology, Huddinge, Sweden
November 1995

103. MS Genetics, Karolinska Hospital, Molecular Medicine Unit, Stockholm, Sweden
November 1995

104. Observations on the Pathogenesis of MS
University of Calgary, CNS Grand Rounds Calgary, AB
November 1995

105. Genetics of MS
The New York Hospital, Cornell Medical Center, Neurology, Neurosurgery & Radiology
Grand Rounds, New York, NY
December 1995

106. New Directions in the Management of MS
Grand Rounds, University of Arkansas, College of Medicine, Little Rock, AR
February 1996

107. Genetics of MS
Atlanta, GA
Advances in MS Conference, Cambridge Healthtech Institute, April 1996

108. Inclusion & Exclusion Criteria for MS Trials
Sixth Modern Management Workshop, “Design & Interpretation of Clinical Trials in MS”,
Stockholm, Sweden
April 1996

109. Genetics of Multiple Sclerosis
13th Meeting on Neuro-transmitters & Disease
Shinjyuku, Tokyo, Japan
June 1996

110. 1. Current Understanding of the Pathogenesis & Natural History of MS; 2. The History of a Disease: Multiple Sclerosis - approaches to the history of neuroscience; 3. Multiple Sclerosis - an example of a complex genetic trait
Neurobiology Review Course Genetic Diseases of the Nervous System, Canadian Congress of Neurological Sciences London, Canada
June 1996

111. The Genetics of MS
University of Oxford, John Radcliffe Hospital, Oxford, UK
September 1996

112. MS Clinical Trials: a critical overview
University of Oxford, John Radcliffe Hospital, Oxford, UK
September 1996

113. Strategies to Identify MS Genes
ECTRIMS, 12th European Congress on MS, Copenhagen, Denmark
September 1996

114. Complex Traits in Neurology
Cornell University Medical College, New York, NY
115. Guidelines for Treatment  
   Toronto Neurology Update  
   November 1996

116. Genetic Susceptibility & Environmental Factors: the Canadian experience  
   ARSEP-MS Research Society, Paris, France  
   December 1996

117. The Pathogenesis of MS & New Treatments  
   Hotel Dieu Grace Hospital, Department of CNS, Windsor, ON  
   December 1996

118. MS Nature vs Nurture  
   Samuel Lunenfeld Research Institute, Mount Sinai Hospital  
   Toronto, ON  
   January 1997

119. Trials on Trial (Overview)  
   Controversies in the Management of Relapsing MS – Symposium, Kananaskis, AB  
   March 1997

120. Techniques & Clinical Implications of Imaging in MS  
   MS Forum - Workshop, Aylesbury, UK  
   April 1997

121. Dissecting a Complex Trait  
   3rd International Symposium -The Molecular Biology of the Nervous System, Toronto, ON.  
   June 1997

122. Genetic Susceptibility in MS  
   17th Blankenese conference, Hamburg, Germany  
   June 1997

123. 1. Issues in Diagnosis, Classification & Prognosis; 2. Lessons from Recent Clinical Trials  
   Conference - MS Clinical Issues & Decisions, Toronto, ON  
   August 1997

124. Genetic & Environmental Basis of Multiple Sclerosis Susceptibility  
   Gordon Research Conference, “Molecular Human Genetics”, Rhode Island  
   August 1997

125. Genetic Studies in MS  
   XVI World Congress of Neurology, Buenos Aires, Argentina  
   September 1997

126. Genetics  
   International Federation of MS Societies, Post-Congress Symposium “Multiple Sclerosis”, Buenos Aires, Argentina  
   September 1997

127. Genetics of MS  
   International Federation of MS Societies, Workshop on the Genetics of MS, Madrid, Spain  
   October 1997

128. Familial MS Research in MS, Istanbul, Turkey  
   13th Congress of the European Committee for Treatment &  
   November 1997

129. Multiple Sclerosis: CPP-income security  
   Programs-Disability Unit, Human Resources Development, London Convention Centre, London, ON  
   March 1998

130. Genetics : physiopathy of multiple sclerosis course  
   Update in Clinical Neurology, Universities of Milan, Pavia, Rome & Messina, Italy  
   March 1998
131. Modern Management
    MS Forum & Workshop, Executive Committee, Lisbon, Portugal
    March 1998

132. Recent Advances in the Treatment of MS
    Canadian Congress of Neurological Sciences, Montreal, Quebec
    June 1998

133. Prognosis for People with MS
    MS Forum Symposium, ECTRIMS, Stockholm, Sweden
    September 1998

134. The Genetics of MS: clinical & scientific applications
    MS Forum Symposium, ECTRIMS, Stockholm, Sweden
    September 1998

135. Betaseron: results of the European Study in Secondary Progressive Multiple Sclerosis
    Schering Satellite Symposium, Stockholm, Sweden
    September 1998

136. The Role of Environmental Factors in MS: introduction
    10th MS Forum Workshop, Montreal, Canada
    October 1998

137. Other Environmental Factors and their Influence on MS
    10th MS Forum Workshop, Montreal, Canada
    October 1998

138. Genetics of MS Symposium on Multiple Sclerosis; new dimensions in basic research & their clinical applications
    Philadelphia, USA
    November 1998

139. Research/Medical Update
    MS Society, Ontario Division Conference, Toronto, Canada
    November 1998

140. Industry/Academic Collaborations and the Olivieri Case
    Berlex Grand Rounds, Mississauga General Hospital,
    Mississauga, Canada
    November 1998

141. A Critique of MR as a Measure of Pathology in MS
    Serono International Symposium - Use of Imaging & Other Monitoring Measurements in Multiple Sclerosis Treatment Strategies, Santa Fe, USA
    November 1998

142. Interferon Beta: Current and Future Use
    Serono International Symposium - Use of Imaging & Other Monitoring Measurements in Multiple Sclerosis Treatment Strategies, Santa Fe, USA
    November 1998

143. Effect of Beta Interferon on Immune Modulation and Natural History
    11th Modern Management Workshop of the MS Forum, Venice, Italy
    March 1999

144. Epidemiology of MS
    Regional North American Annual Meeting of the World Federation of Neuroepidemiology, Research Group on Neuroepidemiology, Toronto, Canada
    April 1999

145. The Unnatural History of Multiple Sclerosis
146. Review of Recent Clinical Trials in MS and The Natural History of Relapsing-remitting and Secondary-progressive MS
    Royal College of Physicians and Surgeons, Dublin, Ireland
    May 1999

147. Natural History of Multiple Sclerosis: the role of MRI as a surrogate outcome measure in multiple sclerosis
    Australian Association of Neurologists, Hobart, Tasmania, Australia
    May 1999

148. Osler’s Contributions to Neurology
    The Osler Club of London
    November 1999

149. Natural History of Multiple Sclerosis
    Institute of Neurology, University College, London
    January 2000

150. Chair, Meeting UK Glial Cell Club, Brunel University, London
    January 2000

151. Pathogenesis of Multiple Sclerosis
    5th Annual Millennium Meeting, Medical Ophthalmological Society, Royal Hallamshire Hospital, Sheffield
    February 2000

152. Prognostic Factors in Multiple Sclerosis
    Gallarate, Italy
    March 2000

153. Relapse Frequency in the First Years Related to Outcome: a 25-years follow-up study in Canadian MS patients
    European Charcot Foundation Symposium
    March 2000

154. How to Assess Prognosis and its Modification in Chronic Neurological Disease
    Neurology for Neuroscientists VI, Oxford
    March 2000

155. Interferons and Glatiramer Acetate in the Treatment of Relapsing Remitting and Secondary Progressive Multiple Sclerosis (Do they prevent the progression of the disease?).
    International Symposium on Multiple Sclerosis, Aula Magna of the University, Palazzo Renata di Francia, Italy
    April 2000

156. Benefits & Drawbacks of Longitudinal Data Collection Over the Methodology Commonly Used in Clinical Trials
    International Workshop on Longitudinal Data Collection in MS, Cairns, Australia
    May 2000

157. The Canadian Collaborative Project on Genetic Susceptibility to Multiple Sclerosis
    AstraZeneca, Sweden
    August 2000

158. Genetics
    1st ESNI Course, Stockholm
    September 2000

159. Observations of the progressive phase of MS
    Italian Society of Neurology, Milan
    September 2000

160. The Natural History of MS
    Across MS Frontiers, The Netherlands
    October 2000

161. Natural History of MS
    1st Congress of LACTRIMS, Buenos Aires
    November 2000

162. The Genetics of MS
    Midland Neurological Society, Coventry
163. Assessment of Randomized Clinical Trials in Chronic Variable Disease
   West London Neuroscience Centre November 2000

164. Epidemiology of Multiple Sclerosis
   Scottish Multiple Sclerosis Symposium, St. Andrews
   December 2000

165. Natural History and Genetics of MS
   Conquering MS, Research in Canada in the New Millennium, Banff, Canada
   December 2000

166. Observations on the Natural History of Multiple Sclerosis
   Postgraduate Centre, Hope Hospital, Salford
   January 2001

167. Genetics of Multiple Sclerosis
   Neurology for Neuroscientists, Magdalen College, Oxford
   March 2001

168. Clinical Trials in Multiple Sclerosis: a critical analysis
   Pharmaceutical & Biotechnology Team Multiple Sclerosis Conference, London
   April 2001

169. Multiple Sclerosis – The Genetics of MS
   Joint Meeting of ABN and Norwegian Society, Oslo, Norway
   May 2001

170. The Natural History of MS Observations from 25,000 Patient Years of Follow-up
   Tokyo, Japan
   May 2001

171. Epidemiology & Genetics of MS
   University College, London
   May 2001

172. The Non-genetic Part of MS Susceptibility: multiple sclerosis 2001, a new era in research and
     therapeutics
     New Jersey Medical School, USA
     May 2001

173. Natural History of MS
     Canadian Congress of Neurological Sciences
     June 2001

174. Lessons from the Natural History of Multiple Sclerosis
     Congress of Epidemiology, Toronto, Canada
     June 2001

175. Autosomal Dominant Episodic Vertigo
     Inaugural Meeting of the British Society of Neuro-Otology, MRC, London
     June 2001

176. CPC: Clinical presentation
     XVII World Congress of Neurology, London
     June 2001

177. MS and/or Migraine
     CFBS Genetics Symposium, Ottawa, Canada
     June 2001

178. Immunogenetics of Autoimmune Disease
     11th International Congress of Immunology, Stockholm
<table>
<thead>
<tr>
<th>Number</th>
<th>Event Title</th>
<th>Location/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>179</td>
<td>Advancing Therapies for MS</td>
<td>Advisory Panel for CNS Medical Group, Bermuda</td>
</tr>
<tr>
<td></td>
<td></td>
<td>July 2001</td>
</tr>
<tr>
<td>180</td>
<td>Heeding the Lessons of Natural History: the importance of attacks in disease progression</td>
<td>Biogen Canada, Parameters of Efficacy in MS: Optimizing the use of Interferons, Niagara, Canada</td>
</tr>
<tr>
<td></td>
<td></td>
<td>August 2001</td>
</tr>
<tr>
<td>181</td>
<td>Immunogenetics: what can it tell us?</td>
<td>VIth International Congress of Neuroimmunology, Edinburgh</td>
</tr>
<tr>
<td></td>
<td></td>
<td>September 2001</td>
</tr>
<tr>
<td>182</td>
<td>Genetics of Multiple Sclerosis</td>
<td>MS Study Day, Neurology Department, The Royal Victoria Infirmary, Newcastle upon Tyne</td>
</tr>
<tr>
<td></td>
<td></td>
<td>October 2001</td>
</tr>
<tr>
<td>183</td>
<td>New Treatment Strategies in MS [symposium]</td>
<td>Biogen, Vienna, Austria</td>
</tr>
<tr>
<td></td>
<td></td>
<td>December 2001</td>
</tr>
<tr>
<td>184</td>
<td>Postgraduate Clinical Neurosciences Series</td>
<td>University of Cambridge Clinical School</td>
</tr>
<tr>
<td></td>
<td></td>
<td>March 2002</td>
</tr>
<tr>
<td>185</td>
<td>The Genetics of MS and Complex Traits</td>
<td>Royal London Hospital, London</td>
</tr>
<tr>
<td></td>
<td></td>
<td>March 2002</td>
</tr>
<tr>
<td>186</td>
<td>Canadian Collaborative Twin Study on Multiple Sclerosis: final report</td>
<td>Association of Physicians Cardiff</td>
</tr>
<tr>
<td></td>
<td></td>
<td>April 2002</td>
</tr>
<tr>
<td>187</td>
<td>Natural History of Multiple Sclerosis, 1st Workshop</td>
<td>Bari, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>May 2002</td>
</tr>
<tr>
<td>188</td>
<td>IFR Neurosciences</td>
<td>Neurosciences Institute, Salpêtrière, Paris</td>
</tr>
<tr>
<td></td>
<td></td>
<td>June 2002</td>
</tr>
<tr>
<td>189</td>
<td>Genetics and Environmental Factors [in MS]</td>
<td>European Neurological Society, 12th Meeting, Berlin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>June 2002</td>
</tr>
<tr>
<td>190</td>
<td>Insights into the Genetics of MS from the Canadian Collaborative Project</td>
<td>ACTRIMS/ECTRIMS 2002, Baltimore</td>
</tr>
<tr>
<td></td>
<td></td>
<td>September 2002</td>
</tr>
<tr>
<td>191</td>
<td>Epidemiology and Genetics of MS: overview of immuno-therapy and role of interferon in MS</td>
<td>International Multiple Sclerosis, Jeddah</td>
</tr>
<tr>
<td></td>
<td></td>
<td>September 2002</td>
</tr>
<tr>
<td>192</td>
<td>Wellcome Trust Gene Centre: genetic studies in MS and in migraine</td>
<td>Neurosciences Meeting, Oxford</td>
</tr>
<tr>
<td></td>
<td></td>
<td>September 2002</td>
</tr>
<tr>
<td>193</td>
<td>Repair of the Central Nervous System</td>
<td>National Multiple Sclerosis Society Workshop, Nice</td>
</tr>
<tr>
<td></td>
<td></td>
<td>October 2002</td>
</tr>
<tr>
<td>194</td>
<td>What We Think We Know</td>
<td>Roundtable on Primary Progressive Disease in MS, Houston</td>
</tr>
<tr>
<td>No.</td>
<td>Event Title</td>
<td>Location/Details</td>
</tr>
<tr>
<td>------</td>
<td>-----------------------------------------------------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>195.</td>
<td>Multiple Sclerosis</td>
<td>Advanced Medical Conference, Royal College of Physicians, London</td>
</tr>
<tr>
<td>196.</td>
<td>Genetics of MS</td>
<td>Neurosciences Seminar, University of Tübingen</td>
</tr>
<tr>
<td>197.</td>
<td>Truth, Knowledge and Power lecture series</td>
<td>St Hugh’s College, University of Oxford</td>
</tr>
<tr>
<td>198.</td>
<td>Genetic Epidemiology of MS</td>
<td>Erasmus MS Centre, Rotterdam</td>
</tr>
<tr>
<td>199.</td>
<td>Natural History of MS</td>
<td>Sylvia Lowry Centre, München</td>
</tr>
<tr>
<td>200.</td>
<td>The Natural History of Untreated MS</td>
<td>2nd Dubrovnik International Conference on MS</td>
</tr>
<tr>
<td>201.</td>
<td>The Natural History of Chronic Variable Disease</td>
<td>MS Forum, 1st Annual Convention, Istanbul</td>
</tr>
<tr>
<td>202.</td>
<td>The Natural History of MS and Relevance of Genes to Outcome</td>
<td>ECTRIMS, Milan</td>
</tr>
<tr>
<td>204.</td>
<td>MS: Disease Course and Natural History; Genetics of MS</td>
<td>1st MS Forum Regional Meeting, Bangkok</td>
</tr>
<tr>
<td>205.</td>
<td>Natural History of MS (2 papers)</td>
<td>Neurological Seminar, Heinrich Heine University, Düsseldorf, Germany</td>
</tr>
<tr>
<td>206.</td>
<td>The Genetics of MS</td>
<td>MRC Immunology Seminar, Imperial College, London</td>
</tr>
<tr>
<td>207.</td>
<td>MS Genetics and the Genetics of Epidemiology</td>
<td>MSc in Human Molecular Genetics Seminar Series, Imperial College, London</td>
</tr>
<tr>
<td>208.</td>
<td>Natural History of MS and the Genetics of MS</td>
<td>2nd International Workshop on Longitudinal Data Collection MS Australia, Hobart, Tasmania</td>
</tr>
<tr>
<td>209.</td>
<td>Historical Evolution of MS</td>
<td>Consortium of MS Centres</td>
</tr>
<tr>
<td>210.</td>
<td>The Vitamin D Story</td>
<td>Canadian Congress of Neurological Sciences, Calgary, Canada</td>
</tr>
<tr>
<td>211.</td>
<td>Natural History and the Relevance of Genes to Outcome</td>
<td></td>
</tr>
</tbody>
</table>
212. Poster presentation
Genomic Imprinting Conference
Montpellier, France  September 2004

213. MS: it is not what it seems
Hôpital Neurologique Pierre Wertheimer
Lyon, France  October 2004

214. Current MS Research and its Potential Clinical Application in the Future
Neurology in the 21st Century
University of Arizona College of Medicine
October 2004

215. MS Genetics
Minisymposium on molecular and therapeutic aspects of MS
King’s College, London, Guy’s Hospital
December 2004

216. Pathogenesis of MS
Wellcome Trust Centre for Human Genetics seminar
Oxford University  April 2005

217. A Critique of Clinical Trials in MS
University of Padua, Italy  May 2005

218. The Genetic Basis of MS
International Symposium on new approaches to understanding
the basis of MS
Valencia, Spain  June 2005

219. Genetic Epidemiology of MS
Baltic Summer School
Copenhagen  August 2005

220. The clinical course of MS: what it tells us about pathogenesis
EFNS Athens  September 2005

221. MS: Evidence that Insufficient Sunlight is a Cause
Meeting on Vitamin D and sunlight
Dept of Health, Portucullis House  November 2005

222. Determining Prognosis in MS/ Environmental Epidemiology of MS/HLA Genes in MS
World Congress in Neurology
Sydney, Australia  November 2005

223. Canadian data
MSRA Symposium on Genetics of MS
Sydney, Australia  November 2005

224. The Eye, the Cord and the Waterhole
Medical Grand Round
JohnRadcliffe Hospital, Oxford  January 2006

225. Multiple Sclerosis: Major Paradigm Shift – the Final Turn?
Internal seminar
Wellcome Trust Centre for Human Genetics, Oxford  January 2006

226. Episodic Ataxia
International Episodic Ataxia Conference
Santa Monica, USA  February 2006
227. The Environmental Epidemiology of MS
   Update in Neurology Symposium
   Cerrahpasa Medical School, University of Istanbul
   March 2006

228. Prevention Possibilities and Challenges in MS
   MS Australia Meeting
   Sydney, Australia
   March 2006

229. Analysis of bias in natural history studies
   ECTRIMS Madrid
   September 2006

230. The Eye, the Cord and the Waterhole
   Medical Grand Round
   John Radcliffe Hospital, Oxford
   January 2006

231. Multiple Sclerosis: Major Paradigm Shift – the Final Turn?
   Internal seminar
   Wellcome Trust Centre for Human Genetics,
   Oxford
   January 2006

232. Episodic Ataxia
   International Episodic Ataxia Conference
   Santa Monica, USA
   February 2006

233. The Environmental Epidemiology of MS
   Update in Neurology Symposium
   Cerrahpasa Medical School, University of Istanbul
   March 2006

234. Prevention Possibilities and Challenges in MS
   MS Australia Meeting
   Sydney, Australia
   March 2006

235. Analysis of bias in natural history studies
   ECTRIMS Madrid
   September 2006

236. Genetic Epidemiology of MS.
   3RD International Course of Neuroepidemiology, Erice, Sicily
   November 2006

237. Are we closer to unlocking the mysteries of MS?
   40th Anniversary meeting of MS Ireland
   March 2007

238. Genetic Epidemiology of MS
   Postgraduate Medical Centre, Gloucester Royal Hospital
   March 2007

239. Multiple sclerosis: evolution and genetics
   Henry Kunkel Society, New York
   April 2007

240. Challenges in conducting a primary prevention trial: Vitamin D and MS
241. MS: pathogenesis and therapeutic interventions.
    Canadian Laboratory Medicine Congress
    Toronto          June 2007

242. MS: the inheritance of susceptibility.
    MS Frontiers London
    June 2007

243. Epidemiology of MS: results from the London Ontario database.
    EFNS, Brussels          August 2007

244. Gene-environment in Multiple Sclerosis
    Istituto Besta. Milan
    October 2007

245. MS Genetics
    ECTRIMS, Prague
    October 2007

246. Genetics in MS: the inheritance of MS susceptibility.
    MS Life Manchester
    March 2008

    Rockefeller University.  April 2008

248. MS and Genetics.
    Royal London Hospital Rounds
    March 2008

249. The inheritance of multiple sclerosis susceptibility.
    Henry Kunkel Society Annual meeting Genoa
    May 2008

250. The Genetics of Outcome
    Institut für Neuroimmunologie und Klinische Multiple
    Sklerose Forschung (inims)
    May 2008

251. Genes and outcomes in MS: predicting disease severity
    WCTRIMS Montreal
    September 2008

252. Debate: Interferons have been shown to prevent long term disability
    Yes: G Comi. It remains uncertain: G.C. Ebers
    CONy
    October 2008

253. National MS Register Audit.
    MS Space Information Event Perth Scotland
    November 2008

254. What does MS Epidemiology in Westerners Take/Teach?
    PACTRIMS Kuala Lumpur
    November 2008
255. Natural History of MS and Genetics of MS.  
   International Update in Clinical Neurosciences  
   Kolkata  
   December 2008

256. Life style changes and demographic patterns of Multiple Sclerosis.  
   ECF Symposium Catania  
   November 2008

257. Time of exposure of environmental factors in Multiple Sclerosis  
   ECF Symposium Catania  
   November 2008

258. The role and mechanisms of HLA in the genetic susceptibility to MS.  
   CHU Hôpital Purpan Toulouse France.  
   April 2009

259. MS research and data. Conference for the Cornell  
   and Memorial Sloan Kettering faculty  
   Cornell University  
   April 2009

260. Vitamin D and MS.  
   Nutritionists in Industry London  
   May 2009

261. The Use of Genetic Approaches in the Study of MS.  
   5th Aegean meeting on Neurologic Therapeutics Heraklion  
   May 2009

262. Vitamin D and genetics in MS  
   MS Life Gateshead  
   June 2009

263. Environment versus or together with genetics”.  
   ECTRIMS Dusseldorf  
   September 2009

   Fison Lecture Kings College  
   October 2009

265. Genetic Epidemiology of MS and Vitamin D.  
   Research Advisory Meeting MS Centre of Excellence Baltimore  
   October 2009

266. The research process illustrated by a “trivial” observation in MS.  
   A-Z of MS London  
   October 2009


268. Family studies in multiple sclerosis: genes and environments

   World Congress of Neurology Bangkok  
   October 2009

270. Genetics of MS XIX  
   AINI Congress, Italy  
   October 2009

271. The Natural History of multiple sclerosis.
Sixth Aegean Meeting on Neurologic Therapeutics. Heraklion
May 2010

272. Pharmacoterrorism. Subtitle (Adult entertainment)
Brasenose Medical Society Oxford May 2010

273. Relapses and Long Term Outcome. MS Debating Society Burnham UK May 2010

274. Debate: Are placebo-controlled clinical trials still ethical/necessary in RRMS?
   Yes: G. Ebers, UK
   No: L. Kappos, Switzerland
   CONy Barcelona October 2010

275. Epidemiology supporting the role of environmental factors in MS.
    ECTRIMS Gothenburg October 2010

276. It’s never been genes or environment. endMS Whistler December 2010

277. Interactions of environment and genes in MS. ECF Symposium Fiuggi December 2010

278. Genetic epidemiology of ms and vitamin d.
    Scottish summit on vitamin D and MS. September 2010

279. Vitamin D and multiple sclerosis.
    Vitamin D: mechanisms in health and disease. QMUL March 2010

280. 3 Healthcare Systems. SENA Southampton October 2010

281. The feasibility of this study for demonstrating a significant reduction of the risk of MS in MS family members: where are the concerns? Epidemiological, ethical, practical, financial.
    ARSEP Paris May 2011

282. MS – a gene environment interaction. Belfast October 2011

283. The Cause of MS.
    Bergen September 2011

284. Vitamin D deficiency
    Scientific symposium to celebrate the 50th anniversary of Multiple Sclerosis Ireland.
    September 2011

285. Effects and complications of long-term treatment in MS you are scheduled to talk for 30-35 minutes on Long-term follow-up studies in MS: what can we expect?
    ENS Lisbon May 2011

286. Month of birth. Cheltenham Science Festival June 2011

287. Genetics and environment. The natural course of Multiple Sclerosis and the personal history of the disease. Data from epidemiology.
    ECF symposium December 2011

289. Environmental factors – targets for preventative strategies in MS.
   ESNI Glasgow--------------------July 2011

290. Healthcare systems I have known. Hurstwood Park, The Princess Royal Hospital. September 2011

291. Clinician scientists – the case for.
   Oxford Integrated Neurology Course.--------------------June 2011

292. Natural History of MS and what it means
   SINS Santiago Chile--------------------July 2011

293. The role of vitamin D in MS. Modern Thinking and MS Management. Birmingham
   February 2012.

294. The case for a prophylactic approach to Public Health and the hidden costs. Chatham House Debate
   Glasgow--------------------March 2012

295. Osler was right about the environment – implications for MS prevention. Osler Club of London
   May 2012

296. Sex ratio in MS – a surrogate for incidence – possible mechanisms. Sex, Gender, and Autoimmunity
   Through the Lifespan.Chicago--------------------May 2012

297. What was learned by listening : MS so far. Oriel Medical Society
   April 2012

298. Life expectancy in MS. 44th Danube Symposium Szeged Hungary
   June 2012

299. Epidemiology & Genetics: what have we missed? Kyoto Japan
   Nov 2013

300. Twenty-five years in the history book of MS: short and long term efficacy and safety with IFNB-1b,
   Society of the Hungarian Neuroimmunologists Esztergom, Hungary
   Nov 2013

301. Debate: Early treatment in MS: Does it make a difference?
   Liverpool, UK--------------------March 2014